New drug cocktail targets Hard-to-Treat ovarian and uterine cancers
NCT ID NCT06107868
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial tests an investigational drug called RP-6306 alongside standard chemotherapy (carboplatin and paclitaxel) in 6 women with recurrent ovarian or uterine cancer that has a specific genetic change (TP53 mutation). The main goal is to find a safe dose and check for side effects. It is a first step to see if this combination might help when other treatments have stopped working.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RP-6306 (a PKMYT1 inhibitor) combined with carboplatin and paclitaxel chemotherapy
- What this could lead to
- If successful, this could lead to a new treatment option for people with recurrent ovarian or uterine cancer that has not responded to standard therapies.
- What could go wrong
- This is a very early, small Phase 1 trial with only 6 participants, focused on safety and dosing. It is too soon to know if the combination will work or be safe for broader use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A lifeline for cancer caregivers: can simple phone support reduce their stress?
- Tissue analysis may guide personalized cancer therapy
- A digital lifeline: could Real-Time symptom tracking transform care for kids with advanced cancer?
- Can a new drug combo shrink Hard-to-Treat salivary gland tumors?
- Can a 30-hour e-learning course equip family doctors to deliver better palliative care?
- Blood test vs. scalpel: could liquid biopsy replace tissue biopsies for cancer monitoring?